nice88 online casino login register

Greenwave Technology Solutions (Nasdaq:GWAV) Secures Ownership of Key Real Estate, Saving $1.7M Annually and Boosting Strategic OpportunitiesYourUpdate TV Speaks with U.S. Chamber of Commerce Foundation about their National Civics Bee Championship

Conference title games a chance at a banner, bragging rights and, for some, a season-wrecking lossNEW YORK and SAN FRANCISCO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nasdaq Private Market (NPM) , a leading provider of secondary liquidity solutions to private companies, employees, and investors, announced today that it has promoted Rotem David, Parul Dubey, Sharif Khaleel, and Chris Setaro to new roles on its Executive Leadership Team. Rotem David has been promoted to Chief Product and Technology Officer (CPTO). At NPM, he is an active member of the company’s Executive Leadership Team. In Mr. David’s new role, he will lead NPM’s product and technology divisions worldwide, responsible for setting and executing the product roadmap as well as effectively bridging the gap between product vision and technical feasibility. He will oversee tech infrastructure, engineering, QA, and product. Mr. David has spent more than 10 years building out NPM’s portfolio of products which offers liquidity and data across various transaction and client types. Prior to NPM, he held lead engineering roles at SecondMarket and Nasdaq, Inc and is credited with helping to pioneer the first tender offer solution revolutionizing the way private companies provide secondary liquidity to their shareholders. Parul Dubey has been promoted to Managing Director and Head of the Private Client Group. In her new role, she now joins the Executive Leadership Team. Ms. Dubey will lead the development of NPM’s retail business to service individuals, family offices, and mid-sized entities. Previously, she was General Manager of the Capital Markets division, where she helped build the business from inception. Ms. Dubey was instrumental in launching several capstone products, including buy-side auctions and SecondMarketTM. Prior to NPM, she worked at Wellington Management as an Investment Specialist responsible for global fund launches and distribution for private equity and healthcare hedge funds. Ms. Dubey also held investment roles at a buyout firm and served on the Board of Steven Feller P.E. (a portfolio company). She started her career at PIMCO, servicing managed separate accounts for sovereign wealth funds, central banks, and family offices in the Middle East and Africa. Sharif Khaleel has been promoted to Managing Director and Head of Institutional Trading. At NPM, he is an active member of the company’s Executive Leadership Team. In his new role, Mr. Khaleel will lead the trading desk, overseeing relationships with institutional clients and broker-dealers. He has nearly 25 years of financial services experience. Prior to NPM, Mr. Khaleel was a Managing Director at Zanbato, where he specialized in executing institutionally sized blocks of private securities. Earlier in his career, he served as a Senior Portfolio Trader at BNY Mellon. Mr. Khaleel has also held various roles on the buy side, including Derivatives and Risk Analyst at Stillwater Investment Management, Senior Trader at Farallon Capital Management, and International Portfolio and Macro Trader at BlackRock, where he spent over four years. Chris Setaro has been promoted to Chief Compliance, Regulatory, and Risk Officer. At NPM, he is an active member of the company’s Executive Leadership Team. Mr. Setaro will now oversee all compliance, regulatory affairs, and risk management functions for the company worldwide. Prior to NPM, he was a Senior Vice President and the Head of Global Risk at Forge Global Inc. Previously, Mr. Setaro was the Global Chief Compliance Officer of SharesPost, Inc. and Chief Compliance Officer for its broker-dealer subsidiary SharesPost Financial Corporation. Earlier in his career, he was a Vice President at Nasdaq, Inc. serving as the Chief Compliance Officer for several of its broker-dealers. “As our business continues to evolve, we are focused on adding talented people and valuable resources to strengthen our company and core products. I am confident that Rotem, Parul, Sharif, and Chris will each position us for continued success and accelerate our ambitions to be a key partner to participants across the private market ecosystem,” said Tom Callahan, Chief Executive Officer, Nasdaq Private Market. “I am proud of their commitment to NPM thus far and look forward to their future contributions.” NPM partners with some of the world’s fastest-growing, venture-backed private companies to facilitate company-sponsored liquidity programs. Its electronic SecondMarketTM trading marketplace is gaining adoption by sellers and buyers who trade private company shares. The company’s Transfer and Settlement product efficiently manages share transfer activity from match through settlement for some of the most sophisticated private companies and investors. Its private market premium data product Tape DTM helps investors and entities better evaluate global investment opportunities. As an industry-leading provider in the secondary market, NPM has executed $55+ billion in transactional value across 760+ company-sponsored liquidity programs for venture-backed private companies as well as 200,000+ individual eligible shareholders and investors. About Nasdaq Private Market Nasdaq Private Market provides liquidity solutions for private companies, employees, and investors throughout each stage of the pre-IPO lifecycle. In 2013, the company was founded within Nasdaq, Inc. Today it is an independent company with strategic investments from Nasdaq, Allen & Company, Bank of America, BNP Paribas, Citi, DRW Venture Capital, Goldman Sachs, HiJoJo Partners, Morgan Stanley, UBS, and Wells Fargo. Learn more at www.nasdaqprivatemarket.com . Visit LinkedIn and X for the latest company news. Media Contacts Nasdaq Private Market Amanda Gold Chief Marketing Officer Amanda.Gold@npm.com Disclosures and Disclaimers NPM is not: (a) a registered exchange under the Securities Exchange Act of 1934; (b) a registered investment adviser under the Investment Advisers Act of 1940; or (c) a financial or tax planner and does not offer legal or financial advice to any user of the NPM website or its services. Securities-related services are offered through NPM Securities, LLC, a registered broker-dealer and alternative trading system, and member FINRA/SIPC. Transactions in securities conducted through NPM Securities, LLC are not listed or traded on The Nasdaq Stock Market LLC, nor are the securities subject to the same listing or qualification standards applicable to securities listed or traded on The Nasdaq Stock Market LLC. Please read these other important disclosures and disclaimers about NPM found here: https://www.nasdaqprivatemarket.com/disclosures-disclaimer/

None

NEW YORK , Nov. 25, 2024 /PRNewswire/ -- Osmo , the digital olfaction company, is rethinking how to identify what's real. Today, Osmo launched AI-powered scent sensors, built to authenticate products in ways barcode and RFID (radio frequency identification) tags never could. [Watch Osmo's scent sensor in action here .] Counterfeiting costs retailers and consumers billions of dollars each year. Osmo's sensors work differently than existing authentication technology: they read the unique scent signatures of authentic products, using AI to identify counterfeits with precision and speed. These sensors aren't just a tool—they're a new way to protect trust at scale. Osmo's approach pairs advanced chemical sensors with AI. By training on massive datasets, these sensors recognize subtle scent patterns, ignore background scents, and deliver clear yes-or-no answers in the field. Embedding these sensors in a retailer's supply chains makes authentication faster, simpler, and more reliable. "What's in the air tells the truth," said Alex Wiltschko , CEO and founder of Osmo. "Our AI sensors listen carefully, cutting through noise to confirm authenticity. They work when older methods fall short, helping businesses and customers get what the genuine products they're paying for and deserve—every time." "Counterfeits are just the beginning," said Rohinton Mehta , former Rapid Evaluation and Project Lead at Google X, now SVP of Hardware and Manufacturing at Osmo. "This same system can help ensure food stays fresh, protect the semiconductor supply chain, and even keep data centers running smoothly. The potential is enormous." What Makes Osmo Different? About Osmo Founded in January 2023 , Osmo launched with $60 million in Series A funding led by Lux Capital and Google Ventures. Osmos's mission is to give computers a sense of smell to improve human health and happiness, combining expertise in AI, chemistry, and engineering to bring scent into the digital age. Osmo has begun work in the fragrance market to create a new generation of better, safer, and more environmentally-friendly scent molecules , designing scent through images or words , and teleporting scent . Beyond fragrance, Osmo is applying its technology in commercial sectors— like detecting counterfeit goods —and public health, where it is discovering new insect repellants . Osmo expects to expand into other industries as the potential for digitized scent grows. Learn more Watch the scent sensor in action: https://youtube.com/shorts/Ce-tEbbpwXo Sign up for the Osmo Community: https://www.osmo.ai/community Press inquiries : press@osmo.ai View original content to download multimedia: https://www.prnewswire.com/news-releases/osmo-introduces-ai-powered-scent-sensors-for-authentication-302315642.html SOURCE Osmo

The Gross Law Firm Notifies Terran Orbital Corporation Investors of a Class Action Lawsuit and Upcoming Deadline – LLAP

The Last Prisoner Project, a nonprofit group working to secure the release of all cannabis prisoners, called on President Joseph Biden this week to use his clemency powers to free thousands of individuals incarcerated for federal marijuana-related offenses that are now legal in many states. The group noted that the president on Monday pardoned two turkeys in an annual Thanksgiving tradition and urged him to “#PardonPeopleNotPoultry.” Members of Congress and justice advocates including the nonprofit group Last Prisoner Project are ... [+] calling on President Biden to release those in prison for marijuana-related offenses. Two years ago, Biden issued a mass pardon for thousands of Americans convicted of federal offenses for simple cannabis possession. He expanded the clemency late last year to include thousands more convicted of use and possession of marijuana on federal lands and the District of Columbia. In a statement, Biden said the pardons reflects his position that “no one should be in jail just for using or possessing marijuana.” “Too many lives have been upended because of our failed approach to marijuana,” he added, according to an October 2022 report from the Associated Press. “It’s time that we right these wrongs.” Despite these actions, the Last Prisoner Project (LPP) notes in a statement that Biden “has yet to release a single person still incarcerated for cannabis through commutation.” Although the pardons granted relief to thousands of people with a conviction on their records, the president’s clemency actions did not address the approximately 3,000 individuals serving time in federal prisons for cannabis related offenses. Less Than 2% Of Clemency Petitions Approved Sarah Gersten, LPP executive director and general counsel, notes in an email that the Biden administration has granted only 1.6% of the clemency petitions submitted during his presidency, according to a report from Axios, the worst in modern presidential history. Additionally, 84% of voters support the release of those incarcerated for offenses that have since been legalized, according to a 2020 ACLU study . 60+ Early Black Friday Deals Worth Shopping Right Now 10 Unofficial Hoka Black Friday Sales You Don’t Want To Miss “If President Biden truly wants to leave a positive legacy on social and racial justice it is imperative that he use the tools afforded to him by the executive clemency power to reform our criminal justice system and release the nearly 3,000 federal cannabis prisoners,” Geller writes. Members Of Congress Call On Biden To Grant Clemency To Cannabis Prisoners Last week, LPP representatives joined members of Congress, justice advocates, formerly incarcerated individuals and their families on the steps of the U.S. Capitol with an open letter to the president. The letter called on Biden to “use your clemency authority to rectify unjust and unnecessary criminal laws passed by Congress and draconian sentences given by judges.” The letter asked the president to issue pardons for those still in federal prison for cannabis offenses before his term ends in January. “We urge you to use your executive clemency power to reunite families, address longstanding injustices in our legal system, and set our nation on the path toward ending mass incarceration,” more than 50 lawmakers wrote in the letter, according to a statement from LPP. Last Prisoner Project is urging President Biden to Pardon People, Not Poultry “While cannabis is now legal in Minnesota and many states across America, thousands remain behind bars in federal prisons for the same substance – a reminder of the work still ahead,” Rep. Ilhan Omar, a Democrat from Minnesota, said on the Capitol steps on November 20. “President Biden still has time to build on his initial pardons and take decisive action. He can extend clemency to every person still serving time for federal cannabis offenses, many of whom have already spent decades behind bars. In Minnesota, we've shown that cannabis legalization and expungement can move hand in hand. Now it's time for federal action to match this progress.” LPP is urging supporters to send a letter to the White House urging President Biden to prioritize granting clemency to those Americans with unjust cannabis sentences over a turkey this Thanksgiving by visiting PeopleNotPoultry.com .VIDEO: Silvertips down Vancover Giants

Macy's finds employee hid $154 million in expenses, report delayed

Delaware judge reaffirms ruling that invalidated massive Tesla pay package for Elon Musk

WASHINGTON (AP) — President-elect Donald Trump's incoming administration is set to be less diverse than President Joe Biden's administration, but several people of color and women appear likely to serve in top roles. While Trump vigorously campaigned against diversity and inclusion efforts in business and government, his Cabinet selections and other high-profile staffing choices include some barrier-breaking nominations. The Cabinet, if confirmed, is set to be one-third women and include some historic firsts. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get any of our free email newsletters — news headlines, obituaries, sports, and more.

Rutgers 77, Georgia Southern 60

New York, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Neuroendocrine Tumors Market to Showcase Rapid Growth During the Study Period (2020–2034), at a CAGR of 5.1%| DelveInsight The launch of upcoming therapies such as ITM-11, CAM2029, RYZ101, CABOMETYX, ALPHAMEDIX, and others in the forecast period, rising incident population due to an increased number of endoscopic and radio-imaging studies, increasing research activities are driving neuroendocrine tumor market size. Companies such as Novartis, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda, and others are competing fiercely to capture the largest market sizes. DelveInsight's latest Neuroendocrine Tumors Market Insights report includes a comprehensive understanding of current treatment practices, emerging neuroendocrine tumor drugs, market share of individual therapies, and current and forecasted neuroendocrine tumors market size from 2020 to 2034, segmented into 6MM [the United States, the EU4 (Germany, France, Italy, and Spain), and the United Kingdom]. Key Takeaways from the Neuroendocrine Tumors Market Report According to DelveInsight's analysis, the market size of neuroendocrine tumors in the US was USD 1.5 billion in 2023. In 2023, Somatostatin analogs (SSAs) captured the highest market size of approximately USD 700 million in the US, followed by LUTATHERA . However, by 2034, radioligand treatments including approved beta emitter-radioligand therapy [LUTATHERA], and most anticipated alpha emitter-based therapies are expected to drive the overall NETs market size. The total number of incident cases of NETs in the US was nearly 29,500 cases in 2023 and is projected to increase by 2034. Prominent emerging companies working in the domain of neuroendocrine tumors, including ITM Solucin GMBH , Camurus , Bristol Myers Squibb , Rayzebio , Exelixis , Ipsen , Takeda , Radiomedix , Orano Med , Perspective Therapeutics , Elicera Therapeutics , Chimerix , Enterome , Teclison , and others, are actively working on innovative neuroendocrine tumor drugs. These novel neuroendocrine tumor therapies are anticipated to enter the neuroendocrine tumors market in the forecast period and are expected to change the market. Some of the key emerging neuroendocrine tumor treatments include ITM-11 (N.C.A. 177LU-EDOTREOTIDE), CAM2029, RYZ101 (ACTINIUM-225 DOTATATE), CABOMETYX (Cabozantinib), ALPHAMEDIX (212PB-DOTAMTATE), [212PB] VMT- -NET , ELC-100 (ADVINCE), ONC201 , EO2401 + NIVOLUMAB , TIRAPAZAMINE (TEC-001) , and others. As the field of radioligand therapy evolves, there is an exciting shift towards alpha-emitting radioisotopes. At present, only beta-emitting radioisotopes are currently approved, companies are now focusing on developing alpha-emitters. In August 2024, Exelixis announced that its supplemental New Drug Application (sNDA) for CABOMETYX has been accepted in the US for: 1) the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated pancreatic neuroendocrine tumors (pNET), and 2) the treatment of adults with previously treated, locally advanced/unresectable or metastatic, well- or moderately differentiated extra-pancreatic NET (epNET). The US Food and Drug Administration (FDA) assigned a standard review with a Prescription Drug User Fee Act (PDUFA) target action date of April 3, 2025. In July 2024 , Curium announced that it had submitted its 505(b)(2) NDA for Lutetium Lu 177 Dotatate Injection for the treatment of somatostatin receptor-positive (SSTR+) GEP-NETS. In April 2024, Novartis announced that the US FDA approved LUTATHERA for the treatment of pediatric patients 12 years and older with SSTR+ GEP-NETs, including foregut, midgut, and hindgut NETs. Discover which therapies are expected to grab the NETs market share @ Neuroendocrine Tumors Market Report Neuroendocrine Tumors Overview Neuroendocrine Tumors (NETs) are a diverse group of cancers that arise from neuroendocrine cells, which have characteristics of both nerve cells and hormone-producing cells. These tumors can develop anywhere in the body but are most commonly found in the gastrointestinal tract, pancreas, and lungs. The exact causes of neuroendocrine tumors are not fully understood, but certain factors may increase risk, including genetic syndromes like multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Lindau disease, and neurofibromatosis. Other potential contributors include chronic inflammatory conditions, smoking, and exposure to certain chemicals. Symptoms of NETs can vary widely depending on the tumor's location and whether it secretes hormones. Some tumors may be asymptomatic for a long time. Common symptoms include abdominal pain, diarrhea, flushing of the skin, unexplained weight loss, and in cases of hormone-secreting tumors, symptoms related to excess hormones, such as changes in blood sugar levels or high blood pressure. Diagnosing NETs typically involves a combination of blood and urine tests to detect hormone levels, imaging studies like CT, MRI, or PET scans, and biopsies to analyze tumor tissue. Specialized tests like chromogranin A (CgA) blood tests or somatostatin receptor scintigraphy (Octreoscan) may also be used to identify neuroendocrine activity and locate tumors. Neuroendocrine Tumors Epidemiology Segmentation The neuroendocrine tumors epidemiology section provides insights into the historical and current neuroendocrine tumors patient pool and forecasted trends for the 6MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The neuroendocrine tumors market report proffers epidemiological analysis for the study period 2020–2034 in the 6MM segmented into: Total Incident Cases of NET Cases of NETs by Grade Stage-specific Cases of NET Cases of NETs by Site Cases of NETs by Functional Status Download the report to understand which factors are driving NETs epidemiology trends @ Neuroendocrine Tumors Epidemiological Insights Neuroendocrine Tumors Treatment Market Surgery is generally considered a first-line treatment for localized NETs. The frontline treatment for metastatic disease is somatostatin analogs, and currently, two agents are FDA-approved: SANDOSTATIN (octreotide acetate) and SOMATULINE DEPOT (lanreotide). Both somatostatin analogs provide symptomatic relief in 50% to 70% of patients and biochemical responses in 40% to 60% of patients. Traditionally, mTOR inhibitor – everolimus or sunitinib – was acknowledged as a second-line agent, but with the recent approval of PRRT (peptide receptor radionuclide therapy), the choice of second-line therapy is debatable. While GEP-NETs in children and adolescents are rare, the impact can be devastating. Advanced Accelerator Applications (AAA)/Novartis's LUTATHERA is now the very first therapy approved specifically for use in pediatric patients with GEP-NETs. offering new hope to young patients living with this rare cancer. In January 2018, the FDA approved LUTATHERA, a radiolabeled somatostatin analog for the treatment of GEP-NETs. In April 2024, Novartis announced that the US FDA approved LUTATHERA for the treatment of pediatric patients 12 years and older with SSTR+ GEP-NETs, including foregut, midgut, and hindgut NETs. LUTATHERA is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs in adults, and in Japan for SSTR-positive NETs. All available therapies for NETs, whether monotherapy or combination, are currently leveraged to treat this complex, diverse population of patients, yet no treatment has maintained progression-free survival (PFS) indefinitely. At present, the NETs market is dominated by SSAs, however, by 2034, radioligand therapies are projected to capture the highest market share, reflecting a paradigm shift driven by their enhanced efficacy and the growing adoption of targeted treatment approaches. While LUTATHERA has primarily been used as a second-line treatment, there is a growing interest in expanding its use to first-line settings for medium- and high-risk NETs. This trend underscores the rising prominence of radioligand therapies in redefining treatment standards in the NETs space. Learn more about the market of NETs @ Neuroendocrine Tumors Treatment Neuroendocrine Tumors Emerging Drugs and Companies Some of the drugs in the pipeline include ITM-11 (ITM Isotope Technologies Munich), CABOMETYX (Exelixis/Ipsen/Takeda), CAM2029 (Camurus), AlphaMedix (Radiomedix/Orano Med), VMT- -NET (Perspective Therapeutics), and others. CABOMETYX (cabozantinib) is a small-molecule inhibitor targeting several receptor tyrosine kinases, such as VEGFRs, MET, RET, and the TAM family (TYRO3, MER, AXL). In August 2024, the FDA accepted a supplemental New Drug Application (sNDA) for cabozantinib to treat patients with advanced pancreatic neuroendocrine tumors (pNET) and extra-pancreatic neuroendocrine tumors (epNET) who have previously undergone treatment. The FDA set a PDUFA target date of April 3, 2025, for review and granted orphan drug designation for pNET. This application is supported by data from the Phase III CABINET trial, which studied CABOMETYX in these patient populations. ITM-11 (177Lu-edotreotide) , developed by ITM Isotope Technologies Munich , is a novel Targeted Radionuclide Therapy that combines two components: Edotreotide (DOTATOC), an octreotide-based somatostatin analog, and EndolucinBeta (n.c.a. lutetium-177 chloride), a low-energy beta-emitting synthetic radioisotope. It is currently under investigation in two Phase III clinical trials: COMPETE (NCT03049189) and COMPOSE (NCT04919226). COMPETE focuses on assessing ITM-11 for treating Grade 1 and Grade 2 GEP-NETs, while COMPOSE investigates its use in patients with well-differentiated high Grade 2 and Grade 3 GEP-NETs. ITM-11 was granted orphan designation for GEP-NET treatment based on Phase II data showing significant improvement in PFS. The other pipeline therapies for neuroendocrine tumors include RYZ101 (ACTINIUM-225 DOTATATE): BRISTOL MYERS SQUIBB/RAYZEBIO CAM2029: Camurus ALPHAMEDIX (212PB-DOTAMTATE): RADIOMEDIX/ORANO MED [212PB] VMT-α-NET: PERSPECTIVE THERAPEUTICS ELC-100 (ADVINCE): ELICERA THERAPEUTICS ONC201: CHIMERIX EO2401 + NIVOLUMAB: ENTEROME TIRAPAZAMINE (TEC-001): TECLISON It is more important than ever to ensure and understand supply chain and manufacturing issues of radiopharmaceuticals to stay at the forefront of radiopharmaceutical innovation, especially since a number of companies are investigating radiopharmaceuticals. Emerging key players should make sure that their product, supply, and production capabilities are adequate, and they should be prepared to meet the challenge of offering new therapeutic approaches to cancer patients who otherwise have limited options. In June 2024, BMS-RayzeBio was forced to pause a phase III trial due to an actinium shortage. Oncolytic virotherapy holds promise for cancer treatment. Oncolytic virotherapies like ELC100 (Elicera Therapeutics) and SVV-001 (Seneca therapeutics) are also being investigated for the treatment of NETs in early clinical trials. The anticipated launch of these emerging therapies are poised to transform the neuroendocrine tumors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the neuroendocrine tumors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about NETs clinical trials, visit @ Neuroendocrine Tumors Treatment Drugs Neuroendocrine Tumors Market Dynamics The neuroendocrine tumors market dynamics are anticipated to change in the coming years. NETs are often diagnosed at an early stage due to the hormonal symptoms they produce, allowing for timely intervention and better outcomes, and with advancements like LUTATHERA being the first therapy specifically approved for pediatric patients with GEP-NETs, along with continued research in targeted therapies such as somatostatin analogs and molecular inhibitors, there are growing opportunities for more effective and personalized treatments ; participation in clinical trials can further drive the discovery of new treatment modalities and improve patient outcomes. Furthermore, many potential therapies are being investigated for the treatment of NETs, and it is safe to predict that the treatment space will significantly impact the NETs market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the NETs market in the 6MM. However, several factors may impede the growth of the neuroendocrine tumors market. Since most of the NET cases comprise GEP-NETs, the lack of awareness among healthcare professionals and the general public often leads to delayed diagnosis and treatment . GEP-NETs are a heterogeneous group of tumors with diverse clinical presentations, making it difficult to develop standardized treatment protocols. Additionally, challenges in research and development , such as limited funding and resources, hinder advancements in the field, while the complexity of diagnosing GEP-NETs increases the risk of misdiagnosis or delayed diagnosis, resulting in suboptimal treatment outcomes. Moreover, neuroendocrine tumor treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the NETs market growth may be offset by failures and discontinuation of emerging therapies , unaffordable pricing , market access and reimbursement issues , and a shortage of healthcare specialists . Neuroendocrine Tumors Report Metrics Details Study Period 2020–2034 Neuroendocrine Tumors Report Coverage 6MM [The United States, the EU-4 (Germany, France, Italy, and Spain), and the United Kingdom] Neuroendocrine Tumors Market Size in the US in 2023 USD 1.5 Billion Key Neuroendocrine Tumors Companies Novartis, Merck, Pfizer, ITM Solucin GMBH, Camurus, Bristol Myers Squibb, Rayzebio, Exelixis, Ipsen, Takeda, Radiomedix, Orano Med, Perspective Therapeutics, Elicera Therapeutics, Chimerix, Enterome, Teclison, and others Key Neuroendocrine Tumors Therapies WELIREG, LUTATHERA, SOMATULINE DEPOT, AFINITOR, SUTENT, SANDOSTATIN LAR DEPOT, SANDOSTATIN, ITM-11 (N.C.A. 177LU-EDOTREOTIDE), CAM2029, RYZ101 (ACTINIUM-225 DOTATATE), CABOMETYX (CABOZANTINIB), ALPHAMEDIX (212PB-DOTAMTATE), [212PB] VMT--NET, ELC-100 (ADVINCE), ONC201, EO2401 + NIVOLUMAB, TIRAPAZAMINE (TEC-001), and others Scope of the Neuroendocrine Tumors Market Report Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and emerging therapies Neuroendocrine Tumors Market Dynamics: Conjoint Analysis of Emerging Neuroendocrine Tumors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Neuroendocrine Tumors Market Access and Reimbursement Discover more about neuroendocrine tumor drugs in development @ Neuroendocrine Tumors Clinical Trials Table of Contents 1 KEY INSIGHTS 2 REPORT INTRODUCTION 3 EXECUTIVE SUMMARY 4 NETS MARKET OVERVIEW AT A GLANCE 4.1 MARKET SHARE DISTRIBUTION (%) BY THERAPIES IN 2020 IN THE US 4.2 MARKET SHARE DISTRIBUTION (%) BY THERAPIES IN 2034 IN THE US 4.3 MARKET SHARE DISTRIBUTION (%) BY LINES OF THERAPIES IN 2020 IN THE US 4.4 MARKET SHARE DISTRIBUTION (%) BY LINES OF THERAPIES IN 2034 IN THE US 5 KEY EVENTS 6 EPIDEMIOLOGY AND MARKET METHODOLOGY 7 DISEASE BACKGROUND AND OVERVIEW 7.1 INTRODUCTION 7.2 SIGNS AND SYMPTOMS 7.3 CLASSIFICATION 7.4 RISK FACTORS 7.5 DIAGNOSIS 7.6 DIAGNOSTIC BIOMARKERS 7.7 DIFFERENTIAL DIAGNOSIS 7.8 STAGING 8 TREATMENT OF NETS 8.1 TREATMENT ALGORITHM 8.2 TREATMENT GUIDELINES 8.2.1 National Comprehensive Cancer Network (NCCN) Guidelines, 2024 8.2.1.1 NCCN Guidelines Version 2.2024 Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract (Well-Differentiated Grade 1/2), Lung, and Thymus 8.2.1.2 NCCN Guidelines Version 2.2024 Well-Differentiated, Grade 3 NETs 8.2.1.3 NCCN Guidelines Version 2.2024 NETs of the Pancreas (Well-differentiated Grade 1/2) 8.2.2 European Neuroendocrine Tumor Society (ENETS) 2023 Guidance Paper for Gastroduodenal NETs G1–G3 8.2.3 European Society for Medical Oncology, 2020 9 EPIDEMIOLOGY AND PATIENT POPULATION 9.1 KEY FINDINGS 9.2 ASSUMPTIONS AND RATIONALE 9.3 THE UNITED STATES 9.3.1 Total Incident Cases of NETs in the United States 9.3.2 Grade-specific Cases of NETs in the United States 9.3.3 Stage-specific Cases of NETs in the United States 9.3.4 Site-specific Cases of NETs in the United States 9.3.5 Cases of NETs by Functional Status in the United States 9.4 EU4 AND THE UK 9.4.1 Total Incident Cases of NETs in EU4 and the UK 9.4.2 Grade-specific Cases of NETs in EU4 and the UK 9.4.3 Stage-specific Cases of NETs in EU4 and the UK 9.4.4 Site-specific Cases of NETs in EU4 and the UK 9.4.5 Cases of NETs by Functional Status in EU4 and the UK 10 PATIENT JOURNEY 11 MARKETED DRUGS 11.1 KEY COMPETITORS 11.2 WELIREG (BELZUTIFAN/MK-6482): MERCK 11.2.1 Product Description 11.2.2 Regulatory Milestones 11.2.3 Other Developmental Activities 11.2.4 Current Pipeline Activity 11.2.4.1 Clinical Trials Information 11.2.5 Safety and Efficacy 11.3 LUTATHERA (LUTETIUM LU 177 DOTATATE): NOVARTIS 11.3.1 Product Description 11.3.2 Regulatory Milestones 11.3.3 Other Developmental Activities 11.3.4 Current Pipeline Activity 11.3.4.1 Clinical Trials Information 11.3.5 Safety and Efficacy 11.4 SUTENT (SUNITINIB MALATE): PFIZER 11.4.1 Product Description 11.4.2 Regulatory Milestone 11.4.3 Safety and Efficacy 11.5 AFINITOR (EVEROLIMUS): NOVARTIS 11.5.1 Product Description 11.5.2 Regulatory Milestones 11.5.3 Safety and Efficacy 11.6 SOMATULINE DEPOT (LANREOTIDE): IPSEN BIOPHARMACEUTICALS 11.6.1 Product Description 11.6.2 Regulatory Milestones 11.6.3 Other Developmental Activities 11.6.4 Safety and Efficacy 11.7 DEMSER (METYROSINE): BAUSCH HEALTH AND ONO PHARMACEUTICAL 11.7.1 Product Description 11.7.2 Regulatory Milestones 11.7.3 Other Developmental Activities 11.7.4 Safety and Efficacy 11.8 AZEDRA (IOBENGUANE I 131; RAIATT MIBG-I 131 INJECTION): PROGENICS PHARMACEUTICALS /LANTHEUS HOLDINGS AND FUJIFILM TOYAMA CHEMICAL 11.8.1 Product Description 11.8.2 Regulatory Milestones 11.8.3 Other Developmental Activities 11.8.4 Safety and Efficacy 12 EMERGING DRUGS 12.1 KEY COMPETITORS 12.2 ITM-11 (N.C.A. 177LU-EDOTREOTIDE): ITM SOLUCIN GMBH 12.2.1 Product Description 12.2.2 Other Developmental Activities 12.2.3 Clinical Development 12.2.3.1 Clinical Trial Information 12.2.4 Safety and Efficacy 12.3 CAM2029: CAMURUS 12.4 RYZ101 (ACTINIUM-225 DOTATATE): BRISTOL MYERS SQUIBB/RAYZEBIO 12.5 CABOMETYX (CABOZANTINIB): EXELIXIS/IPSEN/TAKEDA 12.6 ALPHAMEDIX (212PB-DOTAMTATE): RADIOMEDIX/ORANO MED 12.7 [212PB] VMT-Α-NET: PERSPECTIVE THERAPEUTICS 12.8 ELC-100 (ADVINCE): ELICERA THERAPEUTICS 12.9 ONC201: CHIMERIX 12.10. EO2401 + NIVOLUMAB: ENTEROME 12.11 TIRAPAZAMINE (TEC-001): TECLISON 13 NETS: MARKET ANALYSIS 13.1 KEY FINDINGS 13.2 MARKET OUTLOOK 13.3 CONJOINT ANALYSIS 13.1 KEY MARKET FORECAST ASSUMPTIONS 13.2 UNITED STATES MARKET SIZE 13.2.1 Total Market Size of NETs in the United States 13.2.2 Market Size of NETs by Therapies in the United States 13.3 EU4 AND THE UK MARKET SIZE 13.3.1 Total Market Size of NETs in EU4 and the UK 13.3.2 Market Size of NETs by Therapies in EU4 and the UK 14 NETs Market UNMET NEEDS 15 NETs Market SWOT ANALYSIS 16 NETs Market KOL VIEWS 17 MARKET ACCESS AND REIMBURSEMENT 17.1 UNITED STATES 17.1.1 Centre for Medicare and Medicaid Services (CMS) 17.2 EU4 AND THE UK 17.2.1 Germany 17.2.2 France 17.2.3 Italy 17.2.4 Spain 17.2.5 United Kingdom 17.3 MARKET ACCESS AND REIMBURSEMENT OF NETS 18 APPENDIX 18.1 BIBLIOGRAPHY 18.2 REPORT METHODOLOGY 19 DELVEINSIGHT CAPABILITIES 20 DISCLAIMER 21 ABOUT DELVEINSIGHT Related Reports Neuroendocrine Tumors Epidemiology Forecast Neuroendocrine Tumors Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted NETs epidemiology in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan. Neuroendocrine Tumors Pipeline Neuroendocrine Tumors Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NETs companies, including RayzeBio, Inc., Seneca Therapeutics, Vyriad, Inc., ADC Therapeutics, Eli Lilly and Company, Biotheus Inc., ImmunityBio, Inc., Chimerix, Merck Sharp & Dohme, Oryzon Genomics S.A., CSPC ZhongQi Pharmaceutical Technology, TaiRx, Inc., Betta Pharmaceuticals, Pfizer, NanOlogy LLC, Cardiff Oncology, Luye Pharma Group, Philogen, Hoffmann-La Roche, Regeneron Pharmaceuticals, among others. Gastroenteropancreatic Neuroendocrine Tumors Market Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GEP-NET companies including Novartis, Ipsen Biopharmaceuticals, Pfizer, ITM Isotopen Technologien Muenchen, Camurus AB, Hutchison Medipharma Limited, Bristol-Myers Squibb, Eisai Limite, Experior S.L., Tarveda Therapeutics, Roche Pharma A, Exelixis, Merck Sharp & Dohme Corp, Recordati Inc, Eli Lilly and Company, Genentech, Inc., Aveo Oncology Pharmaceuticals, Radiomedix, Orano Med, PharmaMar, Bayer, Trio Medicines, among others. Gastroenteropancreatic Neuroendocrine Tumors Pipeline Gastroenteropancreatic Neuroendocrine Tumors Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GEP-NET companies, including Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc., Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., Chimerix, among others. Pancreatic Neuroendocrine Tumors Market Pancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PNET companies including Novartis Pharmaceuticals, Pfizer, Keyrus Biopharma, Merck Sharp & Dohme LLC, Pfizer, Apices Soluciones S.L., Pharmacyclics LLC, Ipsen, among others. Oncology Conference Coverage Services DelveInsight's Oncology Conference Coverage Services offer a thorough analysis of outcomes from major events like ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, the European CAR T-cell Meeting, and IASLC. This detailed examination provides businesses with essential insights for competitive intelligence and market trend forecasting, supporting the formulation of future strategies. Other Business Consulting Services Healthcare Competitive Intelligence Healthcare Licensing Services Healthcare Portfolio Management Case Study Learn how the engagement with respected KOLs bolstered the client's reputation as a leader in the pharma industry at KOL Profiling About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn | Facebook | Twitter © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

BISMARCK — North Dakota’s new and returning lawmakers met at the state Capitol in Bismarck on Monday, Dec. 2, commencing the three-day organizational session ahead of the lawmaking season. The organizational session is the time during which lawmakers — namely those who are newly elected — familiarize themselves with the procedures and rules necessary to carry out the lawmaking process. It does not count towards the biennial lawmaking session that begins January and lasts up to 80 days. ADVERTISEMENT Twenty-two new lawmakers are heading into the 69th legislative session, including two members who returned after not being reelected in recent elections: Sen. Richard Marcellais, D-Belcourt, and Rep. Daniel Johnston, R-Kathryn. Day one included the speaker of the House appointment, committee designations and the swearing-in ceremony. The more menial tasks on the agenda for lawmakers involved computer training, seating arrangement and taking fresh headshots. “Times change, things are different. We have to make sure that everybody’s up to speed,” said House Majority Leader Mike Lefor, R-Dickinson. “You’re going to have your agreements, you’re going to have your disagreements," he said. "But it’s all in the spirit of providing the best public policy that we possibly can.” Both House Republicans and Democrats unanimously agreed on nominating Rep. Robin Weisz to serve as speaker of the House. Weisz described the chamber as “the people’s house” while addressing the Legislature from the podium for the first time as speaker. District 41 newcomer Karen Grindberg, R-Fargo, was also unanimously elected by the district to replace Lt. Gov.-elect Michelle Strinden. ADVERTISEMENT “It’s just really exciting how welcoming everybody is and how they want to be helpful,” Grindberg said. Though the intimate details tied to lawmaking are new to the freshman legislator, coming to the Capitol has become second nature. “We used to run around the halls when we were little, that was our favorite thing to do after school," she said. Grindberg’s father was a lawmaker for 22 years and the Republican House Majority Leader. Meanwhile, her husband, Tony Grindberg, was a senator for more than 20 years. She is also the mother of North Dakota Treasurer Thomas Beadle and mother-in-law to Strinden. “I’m excited for the opportunity," Karen Grindberg said. "I want to get to work.” Tuesday’s training will be similar, paying particular attention to ethical topics like workplace harassment and social media conduct. Interim committee findings will also be briefly presented to lawmakers. ADVERTISEMENT The session will conclude Wednesday with the presentation and deliberations of Gov. Doug Burgum’s final budget address. Republicans maintain supermajorities in both chambers, outnumbering Democrats 83-11 in the House and 42-5 in the Senate. Neither party will see different leaders for the 2025 session. Lefor and Senate Majority Leader David Hogue, R-Minot, were reelected during Republican caucus meetings last month. Sen. Kathy Hogan, D-Fargo, and Rep. Zac Ista, D-Grand Forks, were reelected as Senate and House minority leaders during the respective state Democratic-NPL caucases.OLEAN — The chill of winter is here, and to help combat it, the Tri County Arts Council has announced a series of art classes for the month of December. Upcoming classes include: Holiday Basic Stain Glass — Dec. 3 and 10 with Linda Simons from 5-8 p.m.; cost: $100 artisan members and above, $110 basic/family members and non-members, supply fee of $40 is included in cost; ages 16 and up. Live Drawing — Dec. 4 with Violet Nolder from 5-7 p.m.; cost: $10 artisan members and above, $15 basic/family members and non-members; ages 12 and up. Join us for a live drawing session with our costumed model. We will start with some gesture drawing and move to a longer pose. Please note this is not a class with a teacher, but an opportunity to practice your drawing. Stocking Gift Card Holder — Dec. 5 with Michele Mowrer from 5-8 p.m.; cost: $35 artisan members and above, $45 basic/family members and non-members, supply fee of $5 is included in cost; ages 18 and up. In this class, we will be making a Christmas stocking gift card holder. Students will learn pattern making, cutting and the zig zag and straight stitch. We will be using a sewing machine in this class. Students are welcome to bring in their own fabric to use for the project, but this is not required. This is a beginner class, and no experience is needed. Sign up for classes online at: www.tricountyartscouncil.org/classes/ . The Tri-County Arts Council advocates for the creation and appreciation of arts and culture in the region. The TCAC presents 2024 “A Little Something...” Small Works Members Show, featuring over 80 artists and 200 pieces. The show runs now through Jan. 11 in the beautiful Peg Bothner Gallery at the TCAC in Olean. TCAC is always open to the public and adding to their Artisan Market and class schedule and will be open Black Friday from 8 a.m. until to after the parade; Small Business Saturday from 8 a.m. to 4 p.m.; and for the month of December, Tuesday to Friday from 10 a.m. to 5 p.m. and Saturday from 10 a.m. to 4 p.m. Throughout the weekend, there will be several special promotions, including a flash book sale, where you can fill a tote bag with art-related books for just $5; and membership special where you can receive a complimentary TCAC blanket with the purchase of any membership (while supplies last). Finally, save the date for the first Holiday Fine Art and Craft Market held on Dec. 7 from 10 a.m.-5 p.m. at the First National Bank Building, 101 N. Union St. The event will feature several local vendors ranging in mediums from jewelry, pottery, fine art and many more. Find the perfect holiday gifts.